Longboard (LBPH) - כמות מזומנים למניה

Longboard Pharmaceuticals (LBPH) is in the final stages of certification and currently lacks stable cash flow sources. The prospects for Longboard Pharmaceuticals (LBPH) rely on the efficacy and safety of bexazipig in treating epilepsy. The change in cash per share demonstrates liquidity, where 7.38 is recorded as the baseline value. Demand for neuromedicines remains stable and independent of economic fluctuations, ensuring the resilience of sales markets.
פילוחי מדדים מקיפים ואנליטיקה עבור longboardpharma.com (LBPH)

The metric is calculated as the ratio of total liquid assets to the number of shares outstanding. This metric serves as an indicator of financial autonomy and the management's ability to sustain operational activities. For Longboard Pharmaceuticals (LBPH), this cash reserve is critical for financing costly selective inhibitor trials for the FDA. By analyzing the cash per share trend, an investor can assess the company's survival horizon prior to drug commercialization.